AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00514735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Class I or III Antiarrhythmic Medications
Description: Arm 2 (Medical Management): Class I or III antiarrhythmic drugs. Changes in dosing, antiarrhythmic drugs or combinations of antiarrhythmic drugs were allowed. Direct current cardioversions were also allowed at the discretion of the investigator.
Study NCT00335322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz)
Description: Truvada (tenofovir 300mg qd + 200mg qd) once daily Efavirenz 600mg qd once daily
Study NCT00335322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)
Description: Tuvada (tenofovir 300mg qd + 200mg qd) once daily ritoanvir/atazanavir 100mg/300mg qd once daily (taken with food)
Study NCT00335322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
Description: Tuvada (tenofovir 300mg qd + 200mg qd) once daily zidovudine 250mg/300mg qd (taken in two equal doses approximately 12 hours apart) Abacavir 600mg qd
Study NCT03756103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 tablet Dose 1
Description: Oral SPH3127 tablet, a kind of renion inhibitor, 50 mg, once daily for 8 weeks.
Study NCT03756103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 tablet Dose 2
Description: Oral SPH3127 tablet, a kind of renion inhibitor, 100 mg, once daily for 8 weeks.
Study NCT03756103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 tablet Dose 3
Description: Oral SPH3127 tablet, a kind of renion inhibitor, 200 mg, once daily for 8 weeks.
Study NCT03756103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SPH3127 tablet Placebo
Description: Oral SPH3127 tablet placebo, once daily for 8 weeks.
Study NCT01570829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dietressa
Description: Oral administration.
Study NCT01570829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration.
Study NCT03588026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVA576
Description: 6 months of treatment, rVA576 plus SOC. Followed by a further 3 months of rVA576 plus SOC. In total, 9 months on rVA576 plus SOC.
Study NCT03588026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care (SOC)
Description: 6 months on SOC followed by 3 months of treatment with rVA576 plus SOC. In total, 3 months on rVA576 plus SOC.
Study NCT01475968 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrafine Air Pollution Particulate Matter
Description: Ultrafine (particle diameter less than 2.5 microns) Air Pollution Particulate Matter, concentrated from the ambient air outside of the Chapel Hill EPA Human Studies Facility
Study NCT01475968 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Filtered Air
Description: Filtered Air
Study NCT02636634 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: imaging
Study NCT00796484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL888
Description: Administered orally
Study NCT03522584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT03522584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03522584 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT03522584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study NCT03522584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypofractionated Image-Guided Radiation Therapy
Description: Undergo HIGRT
Study NCT02165228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Description: Stress reduction class and behavioral intervention
Study NCT02165228 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Enhancement
Description: Nutrition education class and behavioral intervention
Study NCT02916381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEC block + General anaesthesia
Description: Patients will receive an ultrasound-guided PEC block after the induction of general anaesthesia.
Study NCT01019694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combivent CFC-MDI
Description: 36/206 mcg Four times a day (QID)
Study NCT02829853 — intervention group
Intervention type: GENETIC
Intervention: Genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING
Description: Patients with sarcoidosis patients are monitored in the regular follow-up in one of 28 GSF clinical centers. Blood sampling was performed in two 5ml classical heparinized tube, as used for red/white/platelets blood cells analysis. The patients receive complete information on the SARCFAM protocol and sign an informed consent stating that the genetic study will be conducted on the BTNL2 gene and genes related to immunity, including loci other than BTNL2.DNA was extracted from a 1-5 ml sample of blood and stored in frozen conditions until analysis. Genomic DNA is captured using Agilent in-solution enrichment methodology (Human Clinical Research Exome, Agilent) with their biotinylated oligonucleotides probes library, followed by paired-end 75 bases massively parallel sequencing on Illumina HiSEQ 400. For each genomic position, the exomic frequencies (Homo \& HTZ) are determined from all the exomes already sequenced and/or the exome results provided by 1000G, EVS, HapMap database.
Study NCT02089880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-brace
Description: The participant will receive 6 sessions of training over a one month period in using the C-brace in all levels of functional gait. The participant will then continue use of the C-brace for one month following training. The C-Brace from Otto Bock is an orthosis that controls throughout stance and swing phases of gait with a micro-processor (MP) controlled knee.
Study NCT02089880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stance control orthosis
Description: The participant will receive 6 sessions of training over a one month period in using his current stance control knee-ankle-foot orthosis (SCO) in all levels of functional gait. The participant will then continue use of the SCO for one month following training. The SCO controls the knee by maintaining it straight and extended during the stance phase of gait.
Study NCT00362518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Study Arm A
Description: Control: no vitamins (placebo only). This study will provide baseline metabolic and surrogate marker changes that are caused by the high fat meal. Study arms B, C, and D will be statistically compared to this study.
Study NCT00362518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Study Arm B
Description: This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a low dosage form of vitamin C is administered (250 mg) and Vitamin E (200 IU).
Study NCT00362518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Study Arm C
Description: This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a medium dosage form of vitamin C administered (500 mg)and Vitamin E (400 IU).
Study NCT00362518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Study Arm D
Description: This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a high dosage form of vitamin C is administered (1000 mg) and Vitamin E (800 IU).
Study NCT00003532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Stage III or IV Ovarian Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT01290432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inofolic Plus
Description: Inofolic Plus contains folic acid and myoinositol and melatonin
Study NCT01019694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combivent Respimat 20/100 mcg
Description: Open label randomized parallel
Study NCT02270333 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: Treatment group received inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).~The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.~The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department.
Study NCT02270333 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham inspiratory muscle training
Description: Control group received sham inspiratory muscle training (IMT) at fixed workload, 5% of MIP using threshold loading device (POWERbreathe Classic device IMT Technologies Ltd. Birmingham, England).~The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department.
Study NCT00528138 — intervention group
Intervention type: OTHER
Intervention: Laboratory Test
Description: CRP, white blood cell count, hepatic function tests
Study NCT02405520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: low dosage HPV Vaccine
Description: Participants would intramuscularly receive low dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
Study NCT02405520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: medium dosage HPV Vaccine
Description: Participants would intramuscularly receive medium dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
Study NCT02405520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high dosage HPV Vaccine
Description: Participants would intramuscularly receive high dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
Study NCT02405520 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Aluminium Adjuvant
Description: Participants would intramuscularly receive aluminium adjuvant at 0, 1, 6 month for 3 doses.
Study NCT03632382 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3D acquisition of maxillofacial characteristics
Description: A 3D acquisition of maxillofacial characteristics will be performed for each patient in order to validate a predictive model comparable to data obtained by polysomnography
Study NCT01953848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC905
Description: Oral
Study NCT01045746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole-body vibration A
Description: over four weeks, three times a week with 5 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1.
Study NCT01045746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole-body vibration b
Description: over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 5 Hz, Noise 4.
Study NCT03528018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REACt system
Description: The REACt system is a virtual reality-based paradigm for upper limb rehabilitation that allows for interaction of individuals with restricted movements from active responses triggered when they attempt to perform a movement. The experimental system also provides multisensory stimulation in the visual, auditory, and tactile channels, and transcranial direct current stimulation coherent to the observed movements
Study NCT03528018 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical therapy
Description: Physical therapy included passive and active mobilization of the paretic upper limb. Passive range of motion exercises were provided in those segments where no active movement was detected to meticulously reproduce a range of articular movements and muscle and soft tissue elongation. In case of residual active movement capability, participants were encouraged to perform the movements with the assistance of the therapists
Study NCT03528018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Physical therapy included passive and active mobilization of the paretic upper limb. Passive range of motion exercises were provided in those segments where no active movement was detected to meticulously reproduce a range of articular movements and muscle and soft tissue elongation. In case of residual active movement capability, participants were encouraged to perform the movements with the assistance of the therapists
Study NCT02657980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yband(YDT-201N)
Description: transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
Study NCT02657980 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-Yband(YDT-201N)
Description: transcranial Direct Current Stimulation (tDCS) 2mA for 30 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
Study NCT03595644 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT+TKI
Description: Received SBRT after three months after EGFR-TKI treatment
Study NCT03595644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TKI
Description: Received EGFR-TKI treatment
Study NCT01211925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: distal venous arterialisation
Description: The investigators perform reverse revascularisation of the ischemic limb with arterial blood supply from patent in flow artery to the superficial dorsal venous arch.
Study NCT01211925 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Aspirin
Description: 100 mg per day continuous
Study NCT03146624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: attachment retained obturator
Description: obturator which retained by attachment
Study NCT03146624 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clasp retained obturator
Description: obturator which retained by clasp
Study NCT04089033 — intervention group
Intervention type: PROCEDURE
Intervention: Pneumatic Retinopexy
Description: The PnR technique is performed as per the PIVOT trial under local anaesthetic. First, patients will undergo a thorough scleral-depressed peripheral retinal examination to identify all pathologic features. Second, laser retinopexy will be applied to all breaks, lattice degeneration, or both in the attached retina before gas injection. Third, breaks in the detached retina will be treated with cryotherapy before gas injection or (preferably) laser retinopexy 24 to 48 hours after gas injection, with additional laser retinopexy applied at any point per surgeon discretion. Finally, anterior chamber paracentesis will be used to express as much fluid as safely possible (generally 0.3ml), followed by intravitreal injection of 100% SF6 (ideally 0.6 ml). Patients will be positioned face down for 6 hours and then raise their head 30 degrees every hour (steam roll) and then positioned to the responsible break.
Study NCT04089033 — intervention group
Intervention type: PROCEDURE
Intervention: Pars Plana Vitrectomy
Description: For PPV, a standard 3-port PPV (23 or 25-gauge) will be performed, including posterior hyaloid detachment, core vitrectomy and 360 peripheral vitreous shave. Subretinal fluid will be drained either through the peripheral break or through a posterior retinotomy with use of heavy liquid to assist with appropriate drainage at the discretion of the responsible surgeon. A complete air-fluid exchange will be performed. Endolaser Retinopexy or transconjunctival cryopexy will be performed to treat any retinal pathology, including lattice degeneration and breaks in the attached and detached retina. A iso-expansible concentration of SF6 or C3F8 gas will be injected at the completion of the surgery. Choice of gas will be at the discretion of the responsible surgeon. Patients will be positioned immediately face down for the first 24 hours and then according to the position of the responsible break.
Study NCT01727739 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Linvatec PLLA+TCP
Description: Linvatec PLLA+TCP tibial interference screw fixation will be used in ACL reconstruction.
Study NCT01727739 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Linvatec PLLA
Description: Linvatec PLLA tibial interference screw fixation will be used in ACL reconstruction.
Study NCT01019694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atrovent HFA 42 mcg + Albuterol HFA 200 mcg
Description: Open label randomized parallel
Study NCT00403416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071
Study NCT00403416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic Acid
Study NCT04299672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postural reconstruction
Description: Interventions are described in group descriptions
Study NCT03043508 — intervention group
Intervention type: OTHER
Intervention: Chart Review
Description: Database reviewed to obtain patient and disease characteristics, laboratory values, imaging results, hormone parameters (menopausal status, bioidentical hormone use, oral contraception use, gestational status and diagnosis of a prolactinoma) and vital status.
Study NCT03043508 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history.
Study NCT01568333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given three cycles.
Study NCT01749982 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01749982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline bitartrate
Study NCT01749982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaine
Study NCT01749982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline bitartrate + Betaine
Study NCT03189017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-022
Description: The drug product is a white, round, uncoated tablet.
Study NCT03189017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The placebo is a white, round, uncoated tablet.
Study NCT02677116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Olaratumab administered IV.
Study NCT02677116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin administered IV.
Study NCT02677116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine administered IV.
Study NCT02677116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan administered IV.
Study NCT01902641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinylcholine
Description: Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received succinycholine according to the study group.
Study NCT01902641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium/Sugammadex
Description: Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received rocuronium/sugammadex according to the study group.
Study NCT02677116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide administered IV.
Study NCT02446405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study NCT02446405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAA
Study NCT02446405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRHA or Surgical Castration
Study NCT02446405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRHA or Surgical Castration
Study NCT00535730 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™
Description: 0.65 mL injection Zoster Vaccine, Live, (Oka-Merck) over 4 week vaccination period
Study NCT00535730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™
Description: 0.65 mL injection Zoster Vaccine, Live, (Oka-Merck) over 4 week vaccination period
Study NCT00535730 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (concomitant-vaccine matched)
Description: Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL Placebo injection over 4 week vaccination period.